Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for CLYM116 (Anti-APRIL Antibody) in Iga Nephropathy. The expected timing is based on the latest available company guidance and may change.
05/26/26:- Initial Ph1 healthy-volunteer data for CLYM116 to be presented at ERA June 5, 2026. 06/05/26:- Phase 1 PK/PD and safety update planned for Late Summer 2026. Phase 2 IgAN dosing expected Q3 2026. 08/06/26:- Mabworks Ph1/2 dosing Q3 2026; Ph1 data Sep 3 and Q4; Ph2 data 2027.
Verification
Confirm timing and program details against the company announcement or filing.